Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 2/20 | 0.48 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | TTK | P33981 | 6/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409240 | 0.92 | FYN (0.53) | ZAP70KARS1TTKFYNPDE10A | |
| SCHEMBL12409235 | 0.89 | PAX8 (0.48) | ZAP70KARS1TTKFYNPDE10A | |
| SCHEMBL2178662 | 0.87 | TTK (0.48) | ZAP70KARS1TTKFYNPDE10A | |
| SCHEMBL12409298 | 0.87 | MAPK1 (0.48) | TTKFYNPDE10AGAA | |
| SCHEMBL12409242 | 0.86 | TTK (0.56) | TTKFYNPAX8RXFP1 | |
| SCHEMBL2179881 | 0.85 | CFTR (0.54) | ZAP70KARS1TTKFYNMEN1 | |
| SCHEMBL2178112 | 0.85 | TTK (0.56) | ZAP70KARS1TTKFYNMEN1 | |
| SCHEMBL12409237 | 0.85 | ZAP70 (0.47) | ZAP70KARS1PI4KBTTKFYN | |
| SCHEMBL2182480 | 0.85 | ZAP70 (0.46) | ZAP70KARS1TTKFYNPTGS2 | |
| SCHEMBL12409256 | 0.84 | TTK (0.53) | ZAP70KARS1PI4KBTTKPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | ZAP70 219/4885KARS1 2462/4885PI4KB 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.